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Excessive daytime sleepiness (EDS) is a symptom of obstructive sleep apnea (OSA)
that resolves under treatment with continuous positive airway pressure (CPAP). In some
patients, sleepiness persists despite CPAP treatment. We retrospectively analyzed data
on subjective residual EDS, assessed as an Epworth Sleepiness Scale score (ESS) >10,
in patients from the European Sleep Apnea Database (n= 4,853, mean age± SD 54.8±
11.8 years, 26.1% females), at baseline and at the first visit (median follow-up: 5 months,
interquartile range 3–13). An ESS > 10 occurred in 56% of patients at baseline and in
28.2% of patients at follow-up. Residual EDS was analyzed in 2,190 patients (age: 55.1
± 12.0 years, 26.1% females) with sleep monitoring data (median follow-up: 3 months,
interquartile range 1–15). Sleep studies during CPAP use were obtained in 58% of these
patients; EDS was reported by 47.2% of patients at baseline and by 30.3% at follow-up.
Residual OSA, defined as an apnea–hypopnea index >10/h, and insufficient CPAP
adherence, defined as nightly use <4 h, occurred with similar frequency in patients with
and without EDS at follow-up. Prevalence of residual EDS was highest (40%) in patients
with a first follow-up visit at 0–3 months, then it was 13–19% in patients with a first
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follow-up visit after 4 months to 2 years. The change in ESS (n = 2,190) was weakly
correlated with CPAP use (R2 = 0.023, p < 0.0001). Logistic regression showed that an
ESS score>10 at the first follow-up visit was associated directly with ESS at baseline and
inversely with duration of follow-up, and CPAP use (R2 of the model: 0.417). EDS showed
heterogeneity in different European countries both at baseline and at the first follow-up
visit, suggesting modulation by cultural and lifestyle factors. In conclusion, residual EDS
in CPAP-treated OSA occurred in approximately one in four patients at follow-up; its
prevalence was highest (40%) in the first 3 months of treatment and subsequently
decreased. The finding of residual EDS in a significant percentage of optimally treated
OSA patients suggests that wake-promoting agents may be useful, but their indication
should be evaluated after at least 3 months of treatment.
Keywords: residual sleepiness, CPAP adherence, follow-up, Epworth Sleepiness Scale, sleep duration, sleep
latency
INTRODUCTION
Obstructive sleep apnea (OSA) is characterized by complete or
partial collapse of the upper airway during sleep, intermittent
snoring, increasing inspiratory efforts, sleep fragmentation,
and cyclic hypoxemia and hypercapnia (1). Excessive daytime
sleepiness (EDS) is a major symptom of OSA, occurring in
approximately a quarter to half of OSA patients (1, 2) and is
associated with increased risk of accidents at work or while
driving (3, 4). Continuous positive airway pressure (CPAP) is the
most effective and commonly used treatment for OSA (5). CPAP
application through a tightly fitted nasal or oronasal mask, at a
sufficient pressure level titrated in each patient, prevents upper
airway collapse and the pathophysiological consequences of OSA.
CPAP treatment improves EDS either assessed subjectively by the
Epworth Sleepiness Scale (ESS) or objectively by theMaintenance
of Wakefulness Test (MWT) (5) and prevents sleepiness-related
driving accidents (4).
The effect of CPAP treatment on EDS is multifactorial and
conceptually linked to the improvement of sleep by alleviation
of sleep disordered breathing. Despite a placebo effect (6, 7),
all studies agree that therapeutic CPAP is more effective than
subtherapeutic CPAP, not only on subjective but also on objective
sleepiness measurements. The minimal important difference in
ESS score associated with CPAP use has been estimated as a
decrease in ESS score from baseline between two and three points
(8, 9).
As expected, the CPAP-related improvement in EDS depends
on adherence to treatment and differs according to the
instrument used to assess sleepiness (10). In their seminal paper,
Weaver and coworkers reported that CPAP treatment for 3
months resolved subjective EDS in 66% of adult patients classified
as sleepy at baseline (ESS >10). The frequency of EDS resolution
increased with CPAP use, but ∼20% of the patients remained
subjectively sleepy despite an 8-h nightly use of CPAP (10).
The persistence of EDS in OSA patients treated with
CPAP may be affected by sleep duration, use of drugs, or
comorbid conditions such as depression. After correcting for
such confounding factors, a 6% prevalence of persistent EDS was
estimated in CPAP-treated OSA patients after 1 year of treatment
(11). Variable prevalence rates of residual EDS, between 13 and
40%, have been reported (12–14). Length of follow-up in these
studies varied from 3 to 24 months (12–14). Each of these studies
was conducted in a single country, and the potential influence
of cultural or specific national conditions on residual EDS was
not considered.
The purpose of this study was to assess the current prevalence
of persistent EDS in CPAP-treated OSA patients in the large
European Sleep Apnea Database (ESADA) cohort and to explore
predictors among a large number of factors, including regional
influences. Data were collected after a median CPAP treatment
duration of 5 months.
PATIENTS AND METHODS
The ESADA has prospectively collected data in over 30,000
unselected adult patients (age 18–80 years) with suspected OSA
syndrome studied in several European Centres of SleepMedicine.
A full description of the ESADA Database is available elsewhere
(15). Briefly, collected data at baseline include anthropometrics,
comorbidities, and use of drugs according to Anatomical
Therapeutic Chemical Classification System codes. Sleep data,
collected by polygraphy or polysomnography, include apnea–
hypopnea index (AHI), oxygen desaturation index 3%, mean
and lowest oxygen saturation (SpO2), and time spent at SpO2 <
90% (T90); data on sleep stages were available only in patients
undergoing polysomnography and were not considered in this
analysis. Exclusion criteria in the ESADA cohort are previous
diagnosis of OSA syndrome, limited life expectancy, and current
alcohol or drug abuse. All patients provided written informed
consent for the anonymous use of their data. Each study site
obtained approval of the study by the local ethical committee.
Figure 1 reports the flowchart for inclusion in the study.
Patients who received no treatment, or were treated with bi-
level ventilation, or had incomplete data were excluded. Data
obtained in patients on CPAP treatment at the first follow-up
visit were analyzed to assess the prevalence of residual EDS and
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its predictive factors. Subjective EDS either at baseline or follow-
up was defined as ESS score >10, an ESS score of 10 being the
upper limit recorded in normal subjects (16). Sleep monitoring
data at follow-up (residual AHI, mean hours of CPAP use) and
their source (polysomnography, cardiorespiratory polygraphy,
download of CPAP device) were recorded.
First, the prevalence of residual EDS was assessed on all
patients with data at follow-up (n = 4,853). Then, a detailed
analysis was performed in a subgroup (n = 2,190) with sleep
monitoring data at follow-up (Figure 1). Sleep monitoring (PSG
or PG) on CPAP was obtained in approximately 60% of this
sample (Table 1). To account for possible causes of residual EDS
on CPAP treatment, patients were stratified according to the
occurrence of residual OSA, i.e., AHI ≤ 10 or >10/h, and the
daily adherence to CPAP treatment, i.e., CPAP use<4 or≥4 h. In
addition, in each patient, the change in EDS status from baseline
to follow-up was recorded, and four groups were defined and
further analyzed: EDS at both baseline and follow-up; EDS at
baseline and no EDS at follow-up; no EDS at baseline and EDS
at follow-up, no EDS at either baseline or follow-up.
Statistical analysis: Patients without and with EDS at follow-
up were compared by unpaired t-test for continuous variables
and by χ2 test for categorical variables. One-way analysis of
variance or the Wilcoxon signed-rank test was used to compare
baseline and follow-up data in the four groups defined according
FIGURE 1 | Flow-chart of the study.
TABLE 1 | Source of sleep monitoring data at the first follow-up visit in patients







Polysomnography, n (%) 103 (4.7) 36 (5.4%) 67 (4.4%)
Cardiorespiratory
poligraphy, n (%)
1,405 (54.2%) 523 (78.8%) 882 (62.6%)
Limited channel study, n (%) 4 (0.2%) 2 (0.3%) 2 (0.1%)
Data download, n (%) 678 (31.0%) 103 (15.5%) 575 (40.8%)
to the different combinations of EDS at baseline and follow-
up. Significance was corrected for multiple comparisons. Logistic
regression was used to analyze the factors associated with ESS >
10 at follow-up, based on results of this and previous studies (10–
14, 17). The following variables were tested: age, sex, body mass
index (BMI), ESS, AHI and comorbidities at baseline, subjective
sleep latency at baseline, use of automatic or fixed CPAP, hours of
CPAP use, subjective sleep duration at follow-up, and length of
follow-up. Collinearity among variables was tested by Spearman
rank correlation, and variables with Rho< 0.70 were retained for
analysis. Statview 5.0.1 (SAS Institute) and IBM SPSS Statistics
Version 22 were used for analysis. Statistical significance was at
p < 0.05 for all tests.
RESULTS
The study sample included 4,852 OSA patients on CPAP
treatment at a first follow-up visit. The median follow-up
duration was 5months [interquartile range (IQR): 3–13months].
Compared with baseline ESS score (median and IQR): 10 (6–
14), median ESS score on CPAP treatment was four-point lower
[post-CPAP: 6 (3–10), p < 0.0001]. Subjective EDS was reported
by 56% of patients at baseline and by 28.2% at the first follow-
up visit.
TABLE 2 | Differences at baseline between patients without and with excessive








Age (years) 55.7 ± 11.7 53.9 ± 12.4 0.0015*
Females, n (%) 27.6% 23.4% 0.03
BMI (kg/m2) 33.0 ± 6.6 34.2 ± 6.6 <0.0001*
AHI (events/h) 34.0 [21.0–51.4] 38.0 [23.0–60.0] <0.0001‡
ODI 3% (events/h) 31.0 [18.0–50.9] 38.1 [21.9–59.8] <0.0001‡
Lowest SpO2 (%) 77.1 ± 9.3 76.2 ± 10.0 0.029*
Mean SpO2 (%) 91.9 ± 3.3 91.4 ± 3.4 0.0032*
Time spent at SpO2 <90% (%) 3.9 [0.7–12.5] 5.3 [0.7–14.5] 0.159
‡
ESS score 8 [5–11] 14 [12–17] <0.0001‡
Subjective sleep duration (h) 6.9 ± 1.4 6.7 ± 1.4 0.0017*
Subjective sleep latency (min) 10.0 [5.0–30.0] 5.0 [2.0–20.0] <0.0001‡
Coronary artery disease (%) 8.6% 7.1% 0.25†
Systemic hypertension (%) 49.6% 53.2% 0.12†
Type 2 diabetes (%) 12.4% 14.5% 0.19†
COPD (%) 7.0% 8.1% 0.33†
Asthma (%) 3.6% 2.3% 0.16†
Insomnia (%) 2.1% 1.4% 0.24†
Psychiatric disease (%) 4.8% 3.8% 0.28†
Follow-up duration (months) 5 [1–19] 1[0–7] <0.0001‡
*one-way ANOVA (means±SD); ‡Mann-Whitney U-test test (medians and interquartile
ranges); †χ2 test (percent).
Significantly different variables are marked in bold.
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FIGURE 2 | Analysis of the sample (sleep monitoring data available in 2,190 patients) according to resolution of OSA and adherence to CPAP treatment in patients
without and with EDS at follow-up. Mean ± SD for AHI and CPAP use are reported in each box. Percentage of patients with incomplete OSA resolution or poor CPAP
adherence was similar in patients with and without persistent sleepiness at follow-up (percentages in lower boxes refer to the non-sleepy and sleepy samples,
respectively).
Sleep monitoring data during CPAP were available in 2,190
patients. In these patients, the median follow-up duration was 3
months (IQR 1–15). The prevalence of EDS at baseline (47.2%)
was slightly lower than that found in the entire sample (56%).
ESS score after CPAP treatment was three-point lower than at
baseline [baseline: 10 (6–14), post-CPAP: 7 (4–12), p < 0.0001],
and the prevalence of EDS at follow-up was 30.3%.
Compared with patients without sleep monitoring data
(n= 2,662), patients with sleep monitoring data during CPAP
treatment were of similar age and sex and showed slightly
higher BMI; they reported longer subjective sleep duration and
shorter sleep latency, besides showing a lower AHI, mean and
lowest SpO2, and a similar percentage of time spent at SpO2
< 90%. From a clinical point of view, however, the differences
between groups were small (Supplementary Table 1). The group
with sleep monitoring data showed a lower prevalence of type
2 diabetes, psychiatric disease, and drug treatment compared
with the group without sleep monitoring data at follow-up
(Supplementary Table 1).
Analysis of Patients With Sleep Monitoring
Data at Follow-Up (n = 2,190)
Polysomnography or cardiorespiratory polygraphy was obtained
in 60% of the sample (Table 1). In patients with EDS at follow-
up, data on residual AHI were collected from CPAP devices
in 15.5% of cases. Most patients (81.1%) were treated with
automatic CPAP (Supplementary Table 2). Compared with non-
sleepy patients at follow-up, patients with EDS at follow-up were
more oftenmales, younger andmore obese, showed slightly more
severe OSA, and were sleepier at baseline, whereas comorbidities
were similar in the two groups (Table 2).
Patients were then stratified according to residual AHI (≤10
or >10/h) and adherence to CPAP treatment, i.e., CPAP use <4
or ≥4 h (detailed data are reported in Figure 2). The percentage
of patients with incomplete resolution of OSA, i.e., AHI > 10/h,
and poor CPAP adherence, i.e., <4 h/night, was 2.3% (15/664) in
patients with EDS at follow-up compared with 1.1% (16/1,526) in
patients without EDS at follow-up.
ESS scores were similar in sleepy patients at baseline,
independent of the occurrence of EDS at follow-up (Figure 3A).
A large decrease in ESS was found in sleepy patients at baseline in
whom EDS resolved with CPAP treatment (1 ESS=−8.7± 3.8,
n= 403). Very few (n= 34) of the non-sleepy patients at baseline
(n= 1,157) reported EDS at follow-up (2.9%, 1 ESS= 4.7± 3.9)
(Figure 3B).
At baseline, patients with persistent EDS at follow-up were
more obese than all the other groups and showed the highest
prevalence of type 2 diabetes and the lowest prevalence of asthma;
time to follow-up was also significantly shorter than in all the
other groups (Table 3). Patients with EDS at follow-up showed
the highest AHI and oxygen desaturation index 3%, and lowest
SpO2 variables at diagnosis compared with the other groups;
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FIGURE 3 | (A) Stratification of patients in four groups, according to occurrence of EDS at baseline and follow-up. EDS+: EDS present; BL: Baseline; V1: first
follow-up visit. (B) Change in EDS (1 EDS) in the four groups; 1 EDS calculated as EDS at follow-up minus EDS at baseline.
their median subjective sleep latency at baseline was 5min
compared with values ≥10min in the other groups. Subjective
sleep latency remained low in patients with persistent EDS at
follow-up (Table 4).
A weak relationship was found between hours of CPAP use
and change in ESS (R2 = 0.023, p < 0.0001, n = 2,190). In
patients with EDS at follow-up, the slope of the relationship
between the change in ESS (1 ESS, follow-up minus baseline)
and baseline ESS was less than half the slope found in patients
with resolution of EDS after CPAP treatment (Figure 4). The
prevalence of EDS at follow-up was highest in sleepy patients
at baseline undergoing the follow-up visit in the first 3 months
of treatment; subsequently, the prevalence of persistent EDS
decreased slightly over time, from 21.9% at 3–6 months to 15.1%
at more than 2 years (Figure 5, p for trend < 0.0001).
Logistic regression was used to analyze the predictors of ESS
score >10 at follow-up (n = 2190, R2 of the model: 0.417). The
following variables were identified as correlates:
• ESS at baseline (0.139 [95% CI 0.015/0.263] p= 0.028)
• Hours of nightly CPAP use (−0.514 [95% CI −0.767/–0.261],
p < 0.0001)
• Follow-up duration in months (−0.051 [95% CI
−0.064/−0.039] p < 0.0001)
• Interaction ESS at baseline∗hours of CPAP use/day (0.051
[0.031/0.071, p < 0.0001)
There was a trend for AHI at baseline (−0.006 [95% CI
−0.013/0.001] p = 0.088), and average subjective sleep length
at follow-up (−0.10 [95% CI −0.215/0.013], p = 0.084) to be
inversely related with persistent EDS. Age, sex, BMI, subjective
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Age (years) 53.6 ± 12.4 53.6 ± 11.8 59.2 ± 10.7# 56.4 ± 11.6 <0.0001*
Females (%) 23.3 25.1 20.6 28.1 0.13†
BMI (kg/m2 ) 34.4 ± 6.6 32.7 ± 6.4 30.8 ± 5.4 33.1 ± 6.7 <0.0001*
ESS score at baseline 14.0 [12.0–17.0] 14.0 [12.0–16.0] 9.0 [7.0–10.0]§ 6.0 [4.0–9.0]§ <0.0001‡
Coronary artery disease (%) 6.5 9.3 17.6 8.3 0.07†
Systemic hypertension (%) 53.1 50.8 55.9 49.2 0.42†
Type 2 diabetes (%) 14.9 9.3 5.9 13.6 0.03†
COPD (%) 8.1 5.5 8.8 7.5 0.44†
Asthma (%) 2.2 7.0 5.5 2.7 0.002†
Insomnia (%) 1.3 2.3 2.9 2.1 0.58†
Psychiatric disease (%) 3.8 7.5 2.9 3.8 0.015†
Follow-up duration (months) 1 [0–5] 16 [7–30]§ 14.5 [6.0–43.0]§ 2 [0–12]§ <0.0001‡
*one-way ANOVA, means and SDs; †χ2 test (percent); ‡Kruskal-Wallis test (medians and interquartile ranges). §statistically different compared to the group with EDS at baseline and
at first follow-up visit; #different from groups with EDS at baseline.
Significantly different variables are marked in bold.
sleep latency, comorbidities, or use of fixed or automatic CPAP
did not enter the model. In summary, EDS at follow-up was
associated with high ESS at baseline, short nightly CPAP use,
and short follow-up duration at first control visit. The highly
significant interaction term indicates that a high degree of
sleepiness at baseline reduced the effect of CPAP adherence on
the outcome.
Finally, the geographic distribution of EDS was explored at
baseline and follow-up in the entire sample (n = 4,853). This
analysis was limited to countries with data on at least 50 patients
(50–1,839) (Figure 6). Prevalence of EDS was highly variable,
occurring in 39.8–84.8% of patients at baseline and in 3.6–45.6%
of patients at follow-up. The highest prevalence rates of EDS were
recorded in the samples from Sweden, United Kingdom, and
Ireland at baseline and in the samples from Greece and Ireland
at follow-up.
DISCUSSION
Approximately one in four patients treated with CPAP reported
EDS at follow-up. The prevalence of residual EDS was highest
when the follow-up visit occurred during the first 3 months
of CPAP treatment. Incomplete resolution of OSA and/or poor
adherence to CPAP were similar in patients with and without
EDS at follow-up. The major predictive factors of residual EDS
were baseline EDS, hours of CPAP use, and length of follow-
up. At least part of the variability in EDS at follow-up might be
related to geographical/cultural differences in patients’ samples
or subjective EDS reporting.
The analysis of CPAP-treated OSA patients from the ESADA
cohort revealed a quite high prevalence of EDS at the first
follow-up visit. The sample of treated OSA patients was large
and representative of patients from several European countries.
Importantly, sleep data at follow-up were collected during
sleep studies on CPAP in 45% of the entire sample, and data
downloaded from CPAP devices accounted only for 15.5% of
patients with residual EDS in the sample with sleep monitoring
data during CPAP treatment. Prevalence of EDS at follow-up was
28.2% in the entire sample, highlighting that EDS during OSA
treatment is a clinically relevant, and often overlooked, problem.
Residual EDS was more prevalent in patients assessed early
during follow-up, then its frequency slowly decreased over time.
Compared with patients without EDS at follow-up, patients
with persistent EDS were younger and more obese and showed
slightly more severe OSA at baseline; they were sleepier at
baseline and reported shorter sleep duration and sleep latency,
in agreement with data reported in previous studies on EDS
after treatment. In the study by Pepin and coworkers, patients
with residual EDS were younger and sleepier at diagnosis, but
the prevalence of EDS after 1 year of treatment was lower than
in our study, being 12% in the overall sample, and only 6%
after excluding patients with known causes of EDS, including
restless leg syndrome and depression (11). In the study by
Gasa and coworkers, persistent EDS during CPAP treatment
was associated with baseline ESS score and was more prevalent
in patients with moderate OSA; they also noted that a small
number of non-sleepy patients at baseline became sleepy on
CPAP treatment (5.6 vs. 2.9% in the current study) (12). As
for the possible role of residual AHI or level of adherence to
CPAP treatment, the prevalence of incomplete OSA resolution or
poor CPAP adherence was similar in subjects with and without
persistent EDS. Weaver et al. also reported no difference in
the average use of CPAP between sleepy and non-sleepy OSA
patients at 3-month follow-up (10). The prevalence of EDS
decreased with increasing hours of CPAP use; however, ∼20%
of patients using CPAP for >8 h/night reported residual EDS
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Nocturnal monitoring: BL –
PSG (n) 52 71 8 125
PG (n) 578 332 26 998
limited channel (n) 0 0 0 0
Nocturnal monitoring: FU –
PSG (n) 31 25 5 42
PG (n) 512 100 11 782
limited channel (n) 2 1 0 1
CPAP download (n) 85 277 18 298
AHI (events/h) BL 38.3 [23.0–60.4] 35.0 [18.2–53.9] 24.9§ [13.3–37.4] 33.1§ [21.3–51.0] <0.001‡
FU 3.9 [2.3–5.8] 2.1§ [0.9–4.4] 1.9 [1.0–4.8] 3.1§ [1.4–5.1] <0.0001‡
ODI 3% (events/h) BL 39.2 [22.5–60.7] 30.2§ [15.6–51.0] 17.9§ [12.8–36.6] 31.0§ [19.4–50.8] <0.0001‡
FU 4.2 [2.8–6.3] 2.9§ [0.9–7.0] 3.6 [1.3–17.3] 3.6§ [2.1–5.5] <0.0001‡
Lowest SpO2 (%) BL 75.9 ± 10.0 76.1 ± 10.1 80.9 ± 8.4
§ 77.5 ± 8.9§ 0.0002*
FU 86.0 ± 6.8 82.9 ± 15.2§ 86.9 ± 6.0 86.3 ± 8.8 0.003*
Mean SpO2 (%) BL 91.4 ± 3.4 91.9 ± 3.5
§ 92.4 ± 3.6§ 91.9 ± 3.2§ 0.009*
FU 93.8 ± 4.5 91.2 ± 16.1 95.5 ± 1.4 93.5 ± 8.4 0.02*
Time spent at SpO2 <90% (%
of recorded time)
BL 5.4 [0.7–14.7] 5.3 [1.6–21.2] 3.0 [0.7–10.0] 3.6 [0.6–11.5] 0.025‡
FU 0.2 [0.0–1.4] 0.1 [0.0–2.1] 0.0 [0.0–0.7] 0.1 [0.0–0.9] 0.081‡
Subjective sleep duration (h) BL 6.7 ± 1.4 7.0 ± 1.4§ 7.0 ± 1.2 6.9 ± 1.4§ 0.002*
FU 6.7 ± 1.4 7.0 ± 1.2 6.8 ± 1.2 6.7 ± 1.3 0.046*
Subjective sleep latency (min) BL 5.0 [2.0–25.0] 10.0§ [5.0–30.0] 15.0 [5.0–16.3] 10.0§ [2.0–30.0] <0.0001‡
FU 5.0 [2.0–20.0] 10.0§ [7.0–20.0] 10.0 [2.0–15.0] 10.0§ [2.0–30.0] <0.0001‡
BL, Baseline, FU, first follow-up visit; PSG, Polysomnography; PG, Cardiorespiratory Polygraphy; *one-way ANOVA, means and SDs; ‡Kruskal-Wallis test (medians and interquartile
ranges), §different from the group with EDS at baseline and first follow-up visit.
Significantly different variables are marked in bold.
(10). In the study by Antic and coworkers, 40% of patients with
moderate–severe OSA reported EDS after 3 months of CPAP
treatment (14). Our analysis took into account the length of
follow-up, and, similar to previous results (10, 14), we found a
high prevalence of EDS when the follow-up visit was in the first
3 months of CPAP treatment. We cannot exclude a selection
bias, i.e., patients with persistent EDS may have asked for an
early visit because of problems associated with CPAP treatment.
We also acknowledge that we did not longitudinally assess
patients at different time points during follow-up, and the higher
prevalence of EDS in the first 3 months needs confirmation in
future studies.
Because the sample included patients with and without EDS at
baseline, we analyzed the longitudinal changes in ESS according
to initial and final EDS status. Of 2,190 patients, 47.2% were
sleepy at baseline (n = 1,033), and 61% of them (n = 630)
were sleepy at follow-up. These figures may reflect a selection
bias, i.e., sleep monitoring data would more likely be obtained in
symptomatic than asymptomatic patients at follow-up. Patients
with persistent EDS showed a very short sleep latency compared
with the other groups both at baseline and follow-up. Although
FIGURE 4 | In patients sleepy at baseline, slope of relationship between
change in ESS (1 ESS, EDS at follow-up minus EDS at baseline) and baseline
ESS was much lower in patients with than in patients without EDS at
follow-up. Equations describing regressions are in patients with EDS at
follow-up (red dots): 1ESS = 5.35 – 0.41 • ESS at baseline; R2 = 0.29, p <
0.001; in patients without EDS at follow-up (blue dots): 1ESS: 3.35–0.80 •
ESS at baseline; R2 = 0.68, p < 0.001.
sleep latency is expected to be short in sleepy patients, our
data suggest that a very short sleep latency could help in the
clinical identification of patients more likely to remain sleepy
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FIGURE 5 | Distribution of four groups, stratified based on occurrence of EDS at baseline (BL) and follow-up (V1), according to time of first follow-up visit. Persistent
EDS at follow-up (in red) was more frequent in patients seen during first 3 months of CPAP treatment (p < 0.0001 by X2, p for trend < 0.0001). No EDS BL/No EDS
V1: ESS ≤ 10 at baseline and follow-up; No EDS BL/EDS V1+: ESS ≤ 10 at baseline and ESS > 10 at follow-up; EDS BL + /No EDS V1: ESS > 10 at baseline and
ESS ≤ 10 at follow-up; EDS BL + /EDS V1+: ESS > 10 at both baseline and follow-up.
FIGURE 6 | Prevalence of EDS at baseline and first follow-up visit in different
ESADA countries in entire sample. Only countries reporting data on at least 50
patients are shown.
on CPAP. However, short sleep latency did not enter the
logistic model.
Incomplete resolution of EDS could reflect the individual
susceptibility to hypoxic brain damage or sleep fragmentation.
Convincing data on the pathogenesis of intermittent hypoxia-
induced sleepiness and on the role of sleep fragmentation have
been obtained in rodents. A loss of 40% of wake-promoting
catecholaminergic neurons has been shown in rodents after
chronic intermittent hypoxia exposure for 6 months (18). White
matter damage (19) and possible vicious cycles of oxidative
damage involving both neurons and microglia (20) have been
reported after chronic intermittent hypoxia in mice. Similarly,
neuronal damage was reported in wake active regions after 4
weeks of sleep fragmentation (21). In humans, the mechanisms
preventing full recovery from EDS remain unknown, but imaging
studies hold some promise, as abnormal findings in the frontal
area (22) and white matter alterations (23) were found in patients
with persistent EDS during CPAP treatment. In our study,
ESS scores on CPAP decreased less in patients with persistent
EDS than in patients without EDS at follow-up, for similar
pretreatment ESS levels. This result agrees with the report by
Gasa et al. (12) who found that some improvement in symptoms
occurred with CPAP treatment in patients with persistent EDS
at follow-up, albeit to a lesser extent than patients with no
residual EDS.
A small group of patients not sleepy at baseline became sleepy
on CPAP. These patients were older compared with the other
groups. The low number of patients prevents any meaningful
analysis, but this subgroup may show different clinical features
compared with patients with persistent EDS, i.e., high prevalence
of coronary artery disease or sleepiness due to adverse effects
of CPAP.
The variable prevalence of EDS in different European
countries both at baseline and follow-up may reflect the
variability in several factors, including the local prevalence of
obesity, cultural factors, and lifestyle habits, such as caffeine and
alcohol consumption. This topic deserves further study.
As for factors associated with persistent sleepiness, EDS at
follow-up tended to be negatively related to baseline AHI, in
agreement with the results reported by Gasa et al. (12) who
found that persistent EDS was associated with mild–moderate
OSA rather than severe OSA. Obesity is a potential cause
of daytime sleepiness, even in the absence of OSA (24). The
role of obesity in the pathogenesis of EDS is supported by
its improvement/resolution after weight loss, independently of
Frontiers in Neurology | www.frontiersin.org 8 August 2021 | Volume 12 | Article 690008
Bonsignore et al. Residual EDS in CPAP-Treated OSA
changes in AHI (25). However, BMI did not enter the logistic
model in our study.
Other studies have searched for predictors of persistent EDS in
CPAP-treated OSA patients (12, 26). Our data add the important
information that prevalence of residual EDS in CPAP-treated
patients, after an initial high value during the first 3 months of
treatment, similar to previous studies (10, 14), slowly decreased
during the first 2 years of treatment. This finding opens the
way to pharmacological treatment of EDS. New drugs, i.e.,
solriamfetol and pitolisant, have been recently studied in OSA
patients and appear effective without major adverse effects (27–
29). The indications to drug treatment are still undefined, but
according to our results, it seems advisable that their prescription
should occur at least after 3 months of CPAP treatment.
Our study shows some important limitations. First, sleep
monitoring data were available in only 45.1% of patients
undergoing the first follow-up visit. The analyzed subgroup of
2,190 patients showed a higher prevalence of EDS at follow-
up than the entire sample, suggesting a selection bias. On
the other hand, such an enrichment with a high percentage
of persistently sleepy OSA patients on CPAP may increase
the robustness of the analysis of predictors for persistent
EDS. Moreover, the patients with and without sleep data
at follow-up were similar for anthropometrics and OSA
severity at baseline. Second, the analysis did not take into
account the type of sleep study at baseline or follow-up.
The ESADA cohort includes patients studied at baseline
with either polysomnography or cardiorespiratory polygraphy,
and the impact of different diagnostic methods has been
previously discussed (30). In our study, differences between
polysomnography and cardiorespiratory polygraphy were not
taken into account either at baseline or at follow-up, as this would
have caused a fragmentation of the sample in multiple subgroups
complicating statistical analysis and decreasing statistical power.
On the other hand, data at follow-up were obtained by sleep
studies in many patients, whereas other studies relied exclusively
on data downloaded from CPAP machines (12). Third, the
database does not include depression among the recorded
comorbidities. Depression is recognized as a major risk factor
for EDS in CPAP-treated patients (17). The use of drugs
for depression was reported by a minority of patients (N05-
Psycholeptic drugs by 2.6% and N06-Psychoanaleptics by 6.3%
of the patients), and we cannot exclude that untreated mild
depression might have affected the prevalence of EDS. Finally,
the ESS provides a subjective assessment of EDS, and its reliability
and repeatability have been critically discussed (31, 32). Objective
tests to assess sleepiness would be hardly applicable in large
samples, but differences in ESS scores pre- and posttreatment
were quite large and above the clinically meaningful differences
reported by other studies, making it likely that they reflect
true changes in EDS before–after treatment. In a recent study
assessing objective sleepiness in effectively CPAP-treated patients
with persistent EDS, 19 of 29 subjects (65%) were sleepy or
severely sleepy at the Multiple Sleep Latency Test (33). Moreover,
in the APPLES Study, MWT data were obtained in addition to
ESS after 6 months of CPAP treatment, with good agreement
between the prevalence of subjective and objective EDS. ESS
score >10 was reported by 22% of the sample, and prevalence
of sleep latency < 17min at MWT was 23% (13).
In conclusion, our data provide an estimate of the current
prevalence of persistent EDS in CPAP-treated patients, around
40% in the first 3 months and between 10 and 20% after that.
Occurrence of sleepiness at baseline, CPAP adherence, sleep
duration at follow-up, and the timing of the follow-up visit
predicted explained 40% of the variance in persistent EDS.
Assessment of persistent EDS should be at least after 3 months of
CPAP treatment, as EDS resolves over time in half of the patients
reporting EDS at the start of CPAP treatment.
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